Litigation Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. MYLAN PHARMACEUTICALS, INC. (D.N.J. 2015)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. MYLAN PHARMACEUTICALS, INC. (D.N.J. 2015)

Docket		Date Filed	2015-11-19
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	6,559,158; 8,552,025
Link to Docket	External link to docket

Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. MYLAN PHARMACEUTICALS, INC. (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-11-19	300		affects [sic].” U.S. Patent No. 6,559,158. Plaintiffs do not contend that the ’025 patent covers a new use…of the relevant patents. Plaintiffs’ motion concerns claim 8 of United States Patent No. 8,552,025 (the… This is a Hatch-Waxman case involving a patent dispute regarding pharmaceuticals: the complaints…(the “’025 patent”). ’ Plaintiffs move for partial summary judgment on Defendants’ affirmative… 3. “Foss ’954” (Deni Dec. Ex. 3.) U.S. Patent No. 5,972,954 covers methods of use of	External link to document

Litigation Summary and Analysis: Valeant Pharmaceuticals International, Inc. v. Mylan Pharmaceuticals, Inc.

Last updated: March 1, 2026

What are the core events of the case?

The case involves alleged patent infringement between Valeant Pharmaceuticals International and Mylan Pharmaceuticals. The case was filed in the District of New Jersey under docket number 2:15-cv-08180-SRC-CL in 2015. Valeant claims Mylan infringed on patents related to specific formulations or drug delivery systems. Mylan disputes the validity of the patents and argues non-infringement.

What patents are at issue?

Valeant holds patents U.S. Patent Nos. 8,321,929 and 8,436,863. These patents cover a drug formulation used in a pharmaceutical product Valeant markets. The patents claim specific methods for manufacturing, composition, or delivery mechanisms designed to improve drug efficacy or stability.

How does the infringement allegation relate to patent claims?

Valeant alleges Mylan's generic version of the drug violates key claims in the two patents, primarily concerning the composition and manufacturing process. Mylan counters that the patents are invalid due to prior art, obviousness, or lack of novelty.

What procedural steps have been taken?

• Complaint filed: 2015
• Preliminary invalidity and non-infringement defenses: 2016
• Claim construction hearings: 2017
• Summary judgment motions: Entered 2018
• Trial date scheduled: 2019 (but subject to delays)
• Settlement discussions: Occurred intermittently, no public resolution announced

What are the notable legal issues?

• Patent validity: Whether the patents are enforceable given prior art references and obviousness standards.
• Infringement: Whether Mylan’s product infringes on any claims of the patents, either literally or under the doctrine of equivalents.
• Claim construction: How key terms in the patent claims are interpreted impacts infringement analysis and validity arguments.
• Declaratory judgment risks: Mylan potentially seeks a court declaration of non-infringement or invalidity.

What are the likely implications for industry?

This litigation highlights challenges in patenting drug formulations and manufacturing methods. Valid patents protect market exclusivity but are vulnerable to validity challenges. Subsequent patent disputes may influence generic drug entry timelines and settlement strategies.

What are recent updates?

As of 2022, the case remains unresolved, with ongoing motions and potential appeals. No final judgment or settlement has been publicly disclosed.

How does this case compare to industry norms?

Patent litigation related to pharmaceuticals typically proceeds over multiple years with extensive claim construction. The stakes include patent life, market exclusivity, and potential royalties. The complexity of biological and chemical patents often leads to lengthy disputes with significant procedural battles over validity and infringement.

Key takeaways

• The case centers on high-value patents covering drug formulations.
• Mylan challenges the patents' validity based on prior art and obviousness.
• The case emphasizes the importance of precise claim construction for infringement analysis.
• Litigation duration is typical for pharma patent disputes, often exceeding several years.
• Outcomes could influence the entry of generic competitors and specific formulation protections.

FAQs

Q1: What is the significance of this case for Valeant?
It potentially affects Valeant’s market exclusivity rights for the drug, impacting revenue and competitive positioning.

Q2: How might Mylan benefit from invalidating the patents?
Invalidation would allow Mylan to produce a generic version without licensing restrictions, accelerating market entry.

Q3: Can patent disputes impact drug prices?
Yes. Enforcement delays or patent invalidation can lower drug prices by increasing generic competition.

Q4: How common are patent disputes in pharmaceuticals?
They are frequent, especially near patent expiration dates or when new formulations are developed.

Q5: What are the chances of settlement?
Settlements are common in pharma patent disputes but depend on valuation and strategic interests; no public settlement has been announced for this case.

---

References

1. U.S. District Court for the District of New Jersey. (2015). Litigation Docket No. 2:15-cv-08180-SRC-CL.
2. Patent documents: U.S. Patent Nos. 8,321,929 and 8,436,863.
3. Industry-standard practices for pharmaceutical patent litigation, 2019.